Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Lymphoma, Large-Cell, Anaplastic × lorlatinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 22 Lung Neoplasms 5 Recurrence 3 Non Small Cell Lung Cancer Metastatic 3 Neuroblastoma 3 Neoplasm Metastasis 3 Advanced Non-Small Cell Lung Cancer 2 Thrombocytosis 1 Sexual Dysfunction, Physiological 1 Prostatic Neoplasms 1 Primary Myelofibrosis 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Pancreatic Neoplasms 1 Non Small Cell Lung Cancer ALK Positive or ROS1 Positive 1 Neurofibromatosis 1 1 Neoplasms 1 Neoadjuvant Non-Small Cell Lung Cancer 1 Myeloproliferative Disorders 1 Myelodysplastic-Myeloproliferative Diseases 1 Myelodysplastic Syndromes 1 Multiple Myeloma 1 Meningeal Carcinomatosis 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Large-Cell, Anaplastic 1 Lung Diseases 1 Leukemia, Myelomonocytic, Chronic 1 Leukemia, Myeloid, Chronic-Phase 1 Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1 Leukemia, Myeloid, Acute 1 Leukemia, Myeloid, Accelerated Phase 1

Interventions

Cyclophosphamide 50 fludarabine phosphate 29 Peripheral Blood Stem Cell Transplantation 29 Whole-Body Irradiation 24 Doxorubicin 24 Etoposide 23 Brentuximab Vedotin 23 Vincristine 22 Prednisone 20 Mycophenolic Acid 20 Filgrastim 20 Cyclosporine 19 Rituximab 17 Radiotherapy 14 Methotrexate 14 Cytarabine 13 Busulfan 13 Antilymphocyte Serum 13 Melphalan 12 Tacrolimus 11 Methylprednisolone 10 Flow Cytometry 10 Carboplatin 10 Bortezomib 10 Ifosfamide 9 Magnetic Resonance Spectroscopy 8 Gemcitabine 8 Vorinostat 7 Cisplatin 7 Biopsy 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03505554 2023-08-07

CRU3

University of Milano Bicocca

Phase 2 Unknown

Recurrence, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡